Companies frequently seek to list on an appropriate stock exchange, such as Alternative Investment Market (AIM), as part of their growth strategy. There are many aspects that require careful consideration. Some of them are statutory requirements and others are optional but can benefit the company and help to achieve a successful Initial Public Offering (IPO).
Independent Expert Reports are not a statutory requirement, but many companies realise these are of significant benefit and commission such a report, which will typically cover technical and commercial aspects of the company and the sector in which it operates. PharmaVentures has a strong track record of writing Independent Expert Reports for companies listing on public markets such as AIM.
Adrian Dawkes, Managing Director, gives his expert insight into the use of Independent Expert Reports – the purpose, how to choose an advisory firm to produce it and how it can benefit your IPO process.
This content is restricted to members. To view this content please register or login below to view this content.